Target Disease: Prostate Cancer
The Problem:
- Prostate Cancer is the most common cancer and the second leading cause of cancer death among men in the United States and worldwide
- Global incidence of prostate cancer is increasing in Asia, Northern and Western Europe with potential to increase further in future decades
- As people live longer, Prostate Cancer is a common and important disease creating significant burden to the healthcare system.
- $12 billion spent annually on the treatment of prostate cancer in the US alone
Facts:
- Screening with prostate-specific antigen (PSA) test and the digital rectal exam (DRE) does not provide a definite diagnosis of prostate cancer
- Prostate cancer often has no symptoms until the disease is advanced
- Prostate biopsy has a 30-40% false negative rate requiring stressful, repeat procedures
Opportunity:
- Early stage detection is critical when the chances of treatment success are high
- A multi-modal approach, incorporating Imaging, is widely accepted as optimal
- High interest in the use of Imaging in detecting and managing metastatic Prostate Cancer
- DACI serves as accessory, predictive “value add” to existing tools
